Company · adium-7e18acdd
ADIUM
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. ADIUM. Companies, record adium-7e18acdd. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/adium-7e18acdd
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- ADIUM
- Trials
- 12
- As lead sponsor
- 12
- As collaborator
- 0
- Recruiting
- 0
- Active, recruiting or not
- 0
- Completed
- 12
- Stopped early, withdrawn or suspended
- 0
- Posted results
- 0
- Trials by phase
- Phase 1 1
- Drugs its trials test
- 1
- Comparisons calculated in its trials
- 0
- First trial registered
- 2026-03-18
- Last update
- 2026-08-14
Source ClinicalTrials.gov
Pipeline1
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets |
|---|---|---|---|---|---|---|---|
| EMPAGLIFLOZIN | Not applicable | 1 | 1 | 0 | SLC5A2 | Sodium/glucose cotransporter 2 inhibitor | https://conductscience.org/library/drugs/CHEMBL2107830 |
Source Open Targets
Trials12
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07763964 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study. | Lead sponsor | Not applicable | Completed | Interventional | 46 | 2025-12-08 | https://conductscience.org/library/trials/NCT07763964 | ClinicalTrials.gov | ||
| NCT07763951 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study. | Lead sponsor | Not applicable | Completed | Interventional | 46 | 2025-12-03 | https://conductscience.org/library/trials/NCT07763951 | ClinicalTrials.gov | ||
| NCT07763912 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study. | Lead sponsor | Not applicable | Completed | Interventional | 46 | 2025-11-24 | https://conductscience.org/library/trials/NCT07763912 | ClinicalTrials.gov | ||
| NCT07763899 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study. | Lead sponsor | Not applicable | Completed | Interventional | 46 | 2025-11-19 | https://conductscience.org/library/trials/NCT07763899 | ClinicalTrials.gov | ||
| NCT07698288 | Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fed Conditions | Lead sponsor | Not applicable | Completed | Interventional | 66 | 2026-02-12 | https://conductscience.org/library/trials/NCT07698288 | ClinicalTrials.gov | ||
| NCT07698275 | Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted Conditions | Lead sponsor | Not applicable | Completed | Interventional | 34 | 2026-01-12 | https://conductscience.org/library/trials/NCT07698275 | ClinicalTrials.gov | ||
| NCT07633054 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 500 mg Tablets Under Fed Conditions. | Lead sponsor | Not applicable | Completed | Interventional | 42 | 2025-09-10 | https://conductscience.org/library/trials/NCT07633054 | ClinicalTrials.gov | ||
| NCT07633041 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 1000 mg Tablets Under Fed Conditions. | Lead sponsor | Not applicable | Completed | Interventional | 42 | 2025-02-05 | https://conductscience.org/library/trials/NCT07633041 | ClinicalTrials.gov | ||
| NCT07633028 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 850 mg Tablets Under Fed Conditions. | Lead sponsor | Not applicable | Completed | Interventional | 42 | 2025-02-10 | https://conductscience.org/library/trials/NCT07633028 | ClinicalTrials.gov | ||
| NCT07633015 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 5 mg / 850 mg Tablets Under Fed Conditions. | Lead sponsor | Not applicable | Completed | Interventional | 42 | 2025-02-17 | https://conductscience.org/library/trials/NCT07633015 | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsConditions3
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Bioequivalance | 6 |
| Bioequivalence Study in Healthy Subjects | 4 |
| Bioequivalence | 2 |
Source ClinicalTrials.gov
Partners0
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
None in this release.
Data dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/adium-7e18acdd
GET https://conductscience.org/api/companies/v1/adium-7e18acdd/pipeline